| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIN1 |
| Uniprot No | O00499-7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-439aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAEMGSKGVTAGKIASNVQKKLTRAQEKVL QKLGKADETKDEQFEQCVQNFNKQLTEGTRLQKDLRTYLASVKAMHEASK KLNECLQEVYEPDWPGRDEANKIAENNDLLWMDYHQKLVDQALLTMDTYL GQFPDIKSRIAKRGRKLVDYDSARHHYESLQTAKKKDEAKIAKAEEELIK AQKVFEEMNVDLQEELPSLWNSRVGFYVNTFQSIAGLEENFHKEMSKLNQ NLNDVLVGLEKQHGSNTFTVKAQPSDNAPAKGNKSPSPPDGSPAATPEIR VNHEPEPAGGATPGATLPKSPSQPAEASEVAGGTQPAAGAQEPGETAASE AASSSLPAVVVETFPATVNGTVEGGSGAGRLDLPPGFMFKVQAQHDYTAT DTDELQLRAGDVVLVIPFQNPEEQDEGWLMGVKESDWNQHKELEKCRGVF PENFTERVP |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural insights into BIN1-mediated membrane remodeling"** by Lee et al.
- 摘要：研究通过X射线晶体学解析了BIN1重组蛋白的BAR结构域结构，揭示了其结合细胞膜并诱导膜曲率形成的分子机制，为理解其在神经突触和癌症中的作用提供了结构基础。
2. **"BIN1重组蛋白在阿尔茨海默病中的病理作用"** (Zhang et al.)
- 摘要：通过体外表达BIN1重组蛋白，发现其与Tau蛋白异常互作可能促进神经纤维缠结形成，揭示了BIN1基因变异与阿尔茨海默病风险关联的功能机制。
3. **"Functional characterization of BIN1 isoforms in cardiomyocytes"** by Müller et al.
- 摘要：研究利用重组BIN1蛋白不同剪接变体，证明其在心肌细胞T管系统组装中的关键作用，并发现特定异构体缺失导致心脏收缩功能异常。
4. **"BIN1重组蛋白与肌动蛋白骨架的动态调控"** (Gonzalez-Salgado et al.)
- 摘要：通过体外重构实验证实BIN1重组蛋白通过SH3结构域招募动力蛋白复合物，协调肌动蛋白重塑，为肌营养不良症的分子病理提供了新视角。
(注：以上为模拟文献，实际引用需核对真实数据库如PubMed)
**Background of BIN1 Recombinant Protein**
BIN1 (Bridging Integrator 1), also known as Amphiphysin II, is a ubiquitously expressed protein belonging to the BAR (Bin/Amphiphysin/Rvs) domain family, which plays critical roles in membrane curvature sensing, vesicle trafficking, and cytoskeletal dynamics. Initially identified as a MYC-interacting tumor suppressor, BIN1 is implicated in diverse cellular processes, including endocytosis, apoptosis, and cell cycle regulation. Its functional versatility stems from multiple isoforms generated by alternative splicing, which exhibit tissue-specific expression and distinct subcellular localizations.
In disease contexts, BIN1 has garnered significant attention. In oncology, BIN1 acts as a tumor suppressor, with reduced expression linked to breast, prostate, and colorectal cancers. Conversely, in neurodegenerative disorders like Alzheimer’s disease, BIN1 is the second most significant genetic risk factor after APOE. It interacts with tau protein, influencing its aggregation and pathology. Additionally, BIN1 mutations are associated with centronuclear myopathy, a rare muscle disorder.
Recombinant BIN1 protein, produced via heterologous expression systems (e.g., *E. coli*, mammalian cells), enables detailed biochemical and functional studies. It retains key domains, including the N-terminal BAR domain for membrane binding and the C-terminal SH3 domain for protein-protein interactions. Researchers utilize recombinant BIN1 to investigate its interactions with partners like dynamin, synaptojanin, and tau, as well as its role in membrane remodeling and disease mechanisms. Its applications span *in vitro* assays, structural studies, and drug discovery, particularly for targeting Alzheimer’s or cancer pathways.
Overall, BIN1 recombinant protein serves as a vital tool for elucidating the molecular basis of its multifunctional roles in health and disease.
×
